Ocular immunology and inflammation · 2009
Alopecia areata during etanercept therapy.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pan Ying, Rao Narsing A
Аннотация
PURPOSE: To report a case of alopecia areata occurring during anti-tumor necrosis factor therapy.
METHODS: Observational case report.
RESULTS: The authors describe a 44-year-old man with ankylosing spondylitis who developed 6 months of patchy hair loss consistent with alopecia areata while undergoing treatment with etanercept.
CONCLUSIONS: Although anti-TNF agents are expected to impede autoimmune-related processes such as alopecia areata, these drugs have been found to be causally related to the development of alopecia areata. Ophthalmologists who are increasing involved in using these biologic agents should be aware of possible side effects.
METHODS: Observational case report.
RESULTS: The authors describe a 44-year-old man with ankylosing spondylitis who developed 6 months of patchy hair loss consistent with alopecia areata while undergoing treatment with etanercept.
CONCLUSIONS: Although anti-TNF agents are expected to impede autoimmune-related processes such as alopecia areata, these drugs have been found to be causally related to the development of alopecia areata. Ophthalmologists who are increasing involved in using these biologic agents should be aware of possible side effects.